Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation (NASDAQ:AMRN) presented new data on VASCEPA (icosapent ethyl) at the AHA Virtual Scientific Sessions 2020, reinforcing its effectiveness in reducing major adverse cardiovascular events (MACE) in high-risk patients. Key findings include the unique mechanism of action of eicosapentaenoic acid (EPA) and significant outcomes from the REDUCE-IT trial demonstrating a 24% reduction in MACE for patients with a history of coronary artery bypass grafting. The data supports VASCEPA's cost-effectiveness and its potential for broader use in preventive cardiovascular care.
Amarin Corporation reported significant advancements in the clinical efficacy of VASCEPA® at the AHA Virtual Scientific Sessions 2020. The REDUCE-IT CABG analysis showed a 24% reduction in primary composite major adverse cardiovascular events (MACE) and a 31% decrease in hard MACE among patients with a history of coronary artery bypass grafting (CABG). The absolute risk reductions were 6.2% and 6.0%, with numbers needed to treat of 16 and 17. The data supports VASCEPA's potential role in alleviating risks associated with CABG procedures.
Amarin Corporation, listed on NASDAQ as AMRN, has announced that CEO John F. Thero will present at two upcoming investor conferences in November 2020. The presentations are scheduled for:
- Stifel 2020 Virtual Healthcare Conference on November 16 at 8:40 a.m. ET
- Jefferies Virtual London Healthcare Conference on November 19 at 9:40 a.m. ET
Live audio webcasts will be available on Amarin's website for 30 days. The company is focused on improving cardiovascular health, with its lead product, VASCEPA, currently available in select countries.
Amarin Corporation (NASDAQ: AMRN) reported a significant increase in revenue, with Q3 2020 total revenue up by 39% to $156.5 million and a 56% increase in revenue for the first nine months, totaling $446.8 million, compared to 2019. Despite challenges from the COVID-19 pandemic, VASCEPA's prescription growth also surged, aided by direct-to-consumer advertising. The company is preparing for VASCEPA's European approval, expected in early 2021, while maintaining a robust cash reserve of $608 million. However, the company's net loss increased to $6.8 million for Q3 2020, impacted by rising SG&A expenses.
Amarin Corporation plc (NASDAQ:AMRN) will showcase new research on VASCEPA® (icosapent ethyl) during the AHA Virtual Scientific Sessions 2020 from November 13-17, 2020. Eight presentations will cover significant findings, including the 'REDUCE-IT CABG' results, highlighting the drug's efficacy in reducing major adverse cardiovascular events. Key insights reveal mechanisms of action and clinical outcomes, emphasizing VASCEPA’s role in managing cardiovascular risk in at-risk populations. These findings are expected to enhance understanding and application of icosapent ethyl in clinical settings.
Amarin Corporation presented the REDUCE-IT RENAL results at ASN Kidney Week 2020, highlighting VASCEPA's effectiveness in patients with compromised renal function. Patients with decreased renal function experienced higher cardiovascular event rates but showed significant risk reductions with VASCEPA compared to placebo. The study analyzed the impact across various eGFR categories, revealing consistent benefits in cardiovascular outcomes. Despite increased event rates with impaired renal function, VASCEPA maintained a favorable safety profile. The need for solutions addressing cardiovascular risks in chronic kidney disease remains crucial.
Amarin Corporation plc (NASDAQ:AMRN) presented new real-world data at the American Society of Nephrology Kidney Week 2020, highlighting the link between elevated triglyceride (TG) levels and increased cardiovascular (CV) risk. The analysis, conducted by the U.S. Department of Veterans Affairs, included 152,266 veterans with low-density lipoprotein (LDL)-cholesterol levels managed by statins. Results indicated that 29% of these patients had elevated TG levels and experienced higher rates of major adverse cardiovascular events, reinforcing TG levels as an independent risk factor for CV events in high-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on November 5, 2020, at 7:30 a.m. ET to discuss its third quarter 2020 financial results and provide an operational update. The call will be available on the company's investor relations website or via telephone. A replay will be accessible for two weeks after the call. Investors can submit questions via email until November 4, 2020, at 4:00 p.m. ET. Amarin focuses on improving cardiovascular health, with its lead product, VASCEPA, currently available by prescription in the U.S. and select countries.
Amarin Corporation plc (NASDAQ:AMRN) announced significant findings from the REDUCE-IT PCI study, presented at TCT Connect 2020. VASCEPA® (icosapent ethyl) demonstrated a 34% reduction in primary composite major adverse cardiovascular events (MACE) and a 39% reduction in total MACE for patients with a history of PCI. Absolute risk reductions were 8.5% and 5.4% for key secondary MACE endpoints. The study involved 3,408 patients, highlighting VASCEPA's role in reducing the need for invasive coronary revascularization procedures, which contribute to high healthcare costs.
Amarin Corporation plc (NASDAQ:AMRN) announced promising data from the REDUCE-IT PCI study at TCT Connect 2020, focusing on VASCEPA® (icosapent ethyl) and its impact on patients with a history of PCI. The analysis revealed a 34% reduction in primary composite major adverse cardiovascular events (MACE) and a 39% reduction in total MACE. Key secondary analyses showed similar reductions, with notable absolute risk reductions of 8.5% and 5.4%. These findings support VASCEPA’s role in mitigating risks associated with coronary revascularization, which poses significant healthcare costs.